Clinical Trials Logo

Filter by:
NCT ID: NCT01006252 Terminated - Melanoma Clinical Trials

A Study of Tasisulam-sodium Versus Paclitaxel as Treatment for Metastatic Melanoma

SUMMIT-1
Start date: December 2009
Phase: Phase 3
Study type: Interventional

The primary purpose of this study was to see how tasisulam-sodium affected metastatic melanoma when compared against paclitaxel as measured by overall survival.

NCT ID: NCT01005901 Completed - Clinical trials for Chronic Obstructive Pulmonary Disease

A Study to Assess the Safety, Tolerability and Efficacy of NVA237 Versus Placebo

GLOW 1
Start date: October 2009
Phase: Phase 3
Study type: Interventional

A study to assess the safety, tolerability and efficacy of NVA237 versus placebo in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD).

NCT ID: NCT01005823 Completed - Atopic Dermatitis Clinical Trials

A Safety, Tolerability and Pharmacokinetic Study of LEO 29102 in Subjects With Atopic Dermatitis

Start date: October 2009
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of 7 days treatment with LEO 29102 in adult patients with atopic dermatitis.

NCT ID: NCT01005017 Recruiting - Chronic Pain Clinical Trials

Percutaneous Lesioning Splanchnic Nerves in Patients With Chronic Pancreatitis

PRFLSN
Start date: February 2011
Phase: N/A
Study type: Interventional

Chronic pancreatitis is a progressive inflammatory disease resulting in slow destruction of the pancreas. This chronic inflammation can lead to chronic abdominal pain which can last for many years. Unfortunately, medical management often is of only limited benefit in treating the pain of chronic pancreatitis. Management of patients with intractable pain is difficult, often resulting in narcotic addiction. Early results in a small group of patients suggest that percutaneous radiofrequent lesioning of splanchnic nerves has good potential for pain control in a subset of patients with chronic pancreatitis. Given the simplicity of the procedure, it clearly warrants reappraisal to identify its current role in pancreatic pain management.

NCT ID: NCT01004692 Enrolling by invitation - Clinical trials for Obstructive Sleep Apnea

The Effect of Occlusal Splints on Respiratory Variables in Obstructive Sleep Apnea (OSA) Patients

Start date: December 2008
Phase: Phase 1
Study type: Interventional

Rationale: The effect of vertical dimension on sleep apnoea and respiratory variables in obstructive sleep apnoea patients. Objective: To what extend should a possible worsening of the OSA condition, caused by an increase of mouth opening be taken into consideration in daily dental practice, when an occlusal stabilization splint (OSS) is placed in the mouth. Study design: Cross over RCT-design Study population: OSA patients referred to ACTA from the Slotervaart Hospital, for treatment with a Mandibular Advancement Device (MAD), at least 18 years old. Intervention: Occlusal stabilization splint (OSS) for the upper jaw and a controlled condition in a cross-over design Main study parameters/endpoints: Apnoea- Hypopnoea Index (AHI) and the Epworth Sleepiness Scale (ESS). The aim of this study is to determine the effect of vertical dimension of OS on sleep and respiratory variables in OSA patients. The hypothesis is that insertion of an OSS and an increase of the vertical dimension will result in a significant increase in the AHI.

NCT ID: NCT01004588 Completed - Clinical trials for Muscle Loss in Elderly

The Effects of Resistance Training and Protein Supplementation in Healthy Elderly Men and Women.

Start date: November 2009
Phase: N/A
Study type: Interventional

The main objective of this study is to examine the effects of resistance type exercise training combined with nutritional support on body composition and muscle characteristics in healthy elderly men and women. For a comprehensive insight into the potential underlying mechanisms of the intervention effects on whole body-, muscle- and myocellular level, a broad range of tests will be performed before, during, and after the intervention period.

NCT ID: NCT01004224 Completed - Clinical trials for Advanced Solid Tumors With FGFR1 Amplication

A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies

Start date: December 11, 2009
Phase: Phase 1
Study type: Interventional

The study will determine the maximum tolerated dose and thus the recommended phase II dose and schedule of the compound and characterize the safety.

NCT ID: NCT01004003 Completed - Clinical trials for Carcinoma, Hepatocellular

Phase I/II Comparison of Efficacy and Safety of BIBF 1120 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma

Start date: October 22, 2009
Phase: Phase 2
Study type: Interventional

The study aim is to determine maximally tolerated dose (MTD) of BIBF 1120 in HCC (hepatocellular cancer) and compare efficacy of BIBF 1120 to Sorafenib in HCC patients

NCT ID: NCT01003093 Completed - Tuberculosis Clinical Trials

A Safety and Immunogenicity Trial With an Adjuvanted Tuberculosis(TB) Subunit Vaccine

THYB-01
Start date: November 2005
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety profile of an adjuvanted TB subunit vaccine administered at 0 and 2 months in healthy BCG-unvaccinated volunteers with no prior history of TB disease or known prior exposure to TB

NCT ID: NCT01002833 Completed - Malaria Clinical Trials

Comparison of Three Plasmodium Falciparum Isolates in an Experimental Human Malaria Infection

TIP1
Start date: April 2010
Phase: N/A
Study type: Interventional

Plasmodium falciparum isolates display a wide genetic diversity with possibly different properties to induce immune responses. These properties could directly influence the ability to induce protective efficacy. Since 1998 an experimental human malaria infection model at the Radboud University Nijmegen Medical Center (RUNMC) has been very successful in answering questions with regards to immunological mechanisms of human Pf infection. To date only the NF54 strain of Pf has been deployed in this Nijmegen model. However, investigation of heterologous Pf challenge is not only highly informative for our basic understanding of induction of immune responses but also provides an essential model for protective capacity testing in the clinical development of candidate malaria vaccines. Recently, the parasite culture laboratory of the RUNMC has been able to overcome technical hurdles to produce infectious mosquitoes of two genetically different isolates from different geographical regions to increase the portfolio for Phase IIa trials. These isolates, PfA and PfB will be compared with the NF54 strain for parasitic, immunological and clinical features in humans.